Skip to NavigationSkip to content

Ergomed strengthens management team and board

Published on: 15/07/15

UK-based drug development company Ergomed has appointed Andrew Mackie as chief business officer, and to its board as executive director.

Mackie brings with him over 25 years’ industry experience in pre-clinical research, clinical development and business development, having held a number of senior R&D roles in pharma and biotech companies.

After ten years in R&D, Andrew joined the UK biotech sector in 1997 at Antisoma. He established the clinical development department and transitioned new molecules into development. He later managed Antisoma’s strategic alliance with F Hoffman-La Roche (Now Roche), and in-licensed new drug leads through partnerships and acquisitions.

He joins Ergomed from Eli Lilly, where he was working for the business development team. Prior to this, Mackie was head of life sciences at intellectual property firm IP Group.

Mackie holds a BSc in biochemistry from Queen’s University in Canada, a degree from the University of London and an MBA from the London Business School.

Rolf Stahel, chairman of Ergomed, comments: “I am very pleased to welcome Andrew to the Ergomed board. His expertise and experience will be invaluable as we continue to grow our services and co-development business and expand into new related areas.

Miroslav Reljanovic, chief executive of Ergomed, says: “Over the past ten years, Andrew has worked with Ergomed as a consultant, and has been instrumental in developing the co-development business model, acting as lead negotiator on the partnerships signed to date.”

 

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches